| Biological Information | |
|---|---|
| Background Information: | Ponatinib (or Iclusig) is typically used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. It is intended to be effective against T315I mutated CML. Ponatinib is an inhibitor of multiple tyrosine kinases, including RIPK1, 2, and 3. Provided as 10 mg of dry powder. |
| Target Name: | Ponatinib |
| Usage | |
| Product Type: | Control Ligands & Inhibitors |
| Application: | Drug Discovery & Development |
| Storage Conditions: | Store at -20°C. Please avoid multiple freeze/thaw cycles. |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
| Additional Information | |
| Brand: | DiscoverX |
Ponatinib
Ponatinib is an inhibitor of RIPK1, 2 and 3. This product is provided as 10 mg of dry powder.
Datasheets
92-1315 Datasheet
View Document